Centessa Pharmaceuticals PLC 260-FF:Frankfurt Stock Exchange

RT Quote | Exchange | EUR
Last | 05/03/24 CEST
8.55quote price arrow up+0.25 (+3.01%)
52 week range
3.76 - 11.20
Loading...
  • Open8.50
  • Day High8.55
  • Day Low8.50
  • Prev Close8.30
  • 52 Week High11.20
  • 52 Week High Date03/22/24
  • 52 Week Low3.76
  • 52 Week Low Date05/04/23

Key Stats

  • Market Cap1,032.3M
  • Shares Out112.7M
  • 10 Day Average Volume50
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change23.02

KEY STATS

  • Open8.50
  • Day High8.55
  • Day Low8.50
  • Prev Close8.30
  • 52 Week High11.20
  • 52 Week High Date03/22/24
  • 52 Week Low3.76
  • 52 Week Low Date05/04/23
  • Market Cap1,032.3M
  • Shares Out112.7M
  • 10 Day Average Volume50
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change23.02

RATIOS/PROFITABILITY

  • EPS (TTM)-1.42
  • P/E (TTM)-6.02
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Centessa Pharmaceuticals PLC

 

Profile

MORE
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company's advanced product candidate, SerpinPC, is a subcutaneously administered inhibitor of activated protein C (APC) being developed as a potential treatment for hemophilia. Leveraging its LockBody technology, it is developing an approach to selectively drive potent effector function activity, such as CD47 or CD3, into the tumor microenvironment (TME) while avoiding systemic toxicity. Its first...
Francesco de Rubertis Ph.D.
Independent Chairman of the Board
Saurabh Saha M.D., Ph.D
Chief Executive Officer, Director
Gregory Weinhoff M.D.
Chief Financial Officer
Antoine Yver M.D.
Executive Vice President and Chairman of Development
Address
3Rd Floor, 1 Ashley Road
Altrincham
WA14 2DT
United Kingdom